Pharmaceutical financing continues to be hot, and innovative research and development and cutting-edge technology fields have become hot spots for capital gathering

【Pharmaceutical Network Market Analysis】On September 19, Saipu Bio announced that the company completed a series B financing
of hundreds of millions of yuan.

This round of financing is jointly invested by Yuansheng Venture Capital and CICC Venucia Fund, followed by Xiamen Venture Capital and Zhongxin Group, and the old shareholders Sunshine Ronghui, Oriental Jiafu, Jiale Capital, Yuanhe High Hope, Yuanhe Holdings and Shun Financing Capital continue to be blessed
.

The funds raised will be used to further consolidate the research and development and production of high-end biomedical consumables, accelerate the development and promotion of biopharmaceutical consumables, increase the development of the international market, and move towards
a higher level, a wider range and a deeper field.

It is understood that since the beginning of this year, the domestic medical and medical and health fields have been very hot
.

According to the data, from January to August, there were a total of 1,026 financing events in the national biomedical industry, with a cumulative amount of 89.
174 billion yuan
.

Since September, in addition to Saipu Biologics, a large number of pharmaceutical companies have also announced the completion of financing
.

As the news on September 6, CRO company Huateng Bio announced that it has recently completed a round of financing
.

The funds raised from this round of financing are mainly used for the construction of the Human Disease Large Animal Model Resource Library and the expansion of the capacity
of preclinical CRO services.

Huateng Bio said that it will strive to build itself into the largest R&D and production base for large-scale human disease models of animals in the Guangdong-Hong Kong-Macao Greater Bay Area, and is committed to providing one-stop preclinical evaluation services
for drugs, medical devices, genes and cell therapies.

On September 2, Hangzhou Meisai Biomedical Technology Co.
, Ltd.
announced the completion of a new round of financing
of tens of millions of yuan.

This round of financing is exclusively led by Juming Venture Capital, and the old shareholder Kai Venture Capital continues to invest, and the funds raised will be mainly used for the research and development, product registration and clinical declaration
of existing new targets and new product pipelines.

On the same day, WuXi Biotech Co.
, Ltd.
announced the completion of nearly RMB300 million Series A financing
.

After this financing, the company will accelerate the clinical development and registration of a number of self-developed pipelines
.

.
.
.
.
.
.
From the overall point of view, the pharmaceutical field is relatively gold-absorbing, and the financing amount from January to August has reached 29.
48 billion yuan, accounting for 33.
06%
of the total financing amount.

From the perspective of the number of financing projects, the medical device field is more active, with 342 financing events from January to August, accounting for 33.
3%.


Behind the frequent investment and financing of these tracks, the market prospects of these industries are being widely optimistic by investors for a long time
.

In general, investment and financing data has a predictive effect on the performance of the secondary market, from the current point of view, although the overall heat of the financing market has declined, but the new first-tier and second-tier cities are favored by capital; In addition, although the investment and financing trend in the medical and health field has begun to slow down, the investment opportunities in the medical and health field are still optimistic
in the industry.

The industry expects that in the future, driven by both policies and interests, capital will continue to tilt towards the early investment market; At the same time, more capital will also be invested in innovative research and development and cutting-edge technology fields with original innovative attributes
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.